Market revenue in 2022 | USD 1,625.6 million |
Market revenue in 2030 | USD 2,465.0 million |
Growth rate | 5.3% (CAGR from 2022 to 2030) |
Largest segment | Reagents & consumables |
Fastest growing segment | Reagents & Consumables |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Analyzers, Reagents & Consumables |
Key market players worldwide | BioMerieux SA, Roche Holding AG, Siemens Healthineers AG ADR, Abbott Laboratories, Horiba Ltd, QuidelOrtho Corp, Thermo Fisher Scientific Inc, Biomedica Diagnostics, Werfen, Diazyme Laboratories |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to thrombosis and hemostasis biomarkers market will help companies and investors design strategic landscapes.
Reagents & consumables was the largest segment with a revenue share of 65.61% in 2022. Horizon Databook has segmented the U.S. thrombosis and hemostasis biomarkers market based on analyzers, reagents & consumables covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of the U.S. market can be primarily attributed to the rising demand for point-of-care testing, increasing prevalence of hemostatic and thrombosis disorders, such as Disseminated Intravascular Coagulation (DIC), Pulmonary Embolism (PE), & Deep Vein Thrombosis (DVT), and increasing use of thrombosis & hemostasis biomarkers in drug R&D.
For instance, according to a CDC report published in 2023, the number of people affected due to DVT or PE is about 900,000 in the U.S. every year. It is also estimated that 60,000 to 100,000 deaths occur in the country due to DVT/PE.
Some of the key players in the market are Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott, Diazyme Laboratories, Inc., Sekisui Diagnostics, LLC, and Bio-Rad Laboratories, Inc.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. thrombosis and hemostasis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into U.S. thrombosis and hemostasis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account